Summary A panel of 36 cases of preinvasive breast lesions, including 35 cases of ductal carcinoma in situ (DCIS), has been examined for mutation of TP53, allelic imbalance (Al) on 17pl3, and expression of TP53, in a number of cases, has been studied using immunohistochemistry. Areas of DCIS, with or without adjacent invasive or benign cells, have been separately microdissected from paraffin-embedded sections and analysed by PCR for genetic changes to chromosome l7pl3. TP53 mutations and AI on 17p have been identified in cases of 'pure' DCIS as well as those with associated invasive carcinoma and, furthermore, have been identified in well-differentiated lesions as well as poorly differentiated ones.
The identification of somatic mutations and chromosomal abnormalities occurring in human breast cancer has resulted in an increasingly complex picture of breast tumour development. The difficulty in distinguishing between genetic alterations, which represent key changes, and those which have been randomly acquired, has precluded the identification of events occurring at specific stages of breast tumorigenesis. This is largely owing to the failure of previous studies to focus on different histological subtypes, in particular early-stage breast tumours. However, in contrast to colorectal cancer, where there exists a series of well-defined preinvasive lesions, there is no clear precursor to invasive breast carcinoma. Furthermore, the classification of many early-stage breast lesions is often ambiguous.
A number of epidemiological studies on the risk of developing invasive carcinoma in patients with benign epithelial hyperplasia Page et al., 1985; Tavassoli and Norris, 1990) and with carcinoma in situ (Rosen et al., 1980; Page et al., 1982) do, however, suggest a possible continuum from proliferative epithelial changes of the breast to invasive carcinoma. Ductal carcinoma in situ (DCIS) is one of the earliest recognisable forms of breast cancer. Although cytologically the cells are often indistinguishable from those of invasive carcinoma, they are confined within the basement membrane surrounding the duct and there is no evidence of stromal invasion. As a result of its frequent finding adjacent to invasive carcinoma, and the observation that patients with DCIS have a risk ten times that of the general population of developing invasive breast tumours, often at the site of the original tumour, DCIS appears to be a likely candidate for a precursor lesion of invasive carcinoma (Betsill et al., 1978; Page et al., 1982 Page et al., , 1995 . However, despite its high occurrence, the relationship between DCIS and invasive carcinoma remains unclear. This is largely due to the heterogeneous nature of the lesions which constitute DCIS. The disease consists of three main histological subtypes-comedo, cribriform and micropapillary-which differ in their biological behaviour and prognosis (Page and Rogers, 1987) . In view of this a new classification has been proposed, dividing cases into well, intermediate and poor differentiation (Holland et al., 1994) . In addition, studies on the use of local excision as a possible treatment for DCIS suggest that those patients with the comedo subtype may be at greater risk of local recurrence (Lagios et al., 1982) . That these tumours may represent a more aggressive form of DCIS is also suggested by the findings that alterations to both c-erbB-2 (Gusterson et Van de Vijver et al., 1988; Barnes et al., 1992a) and TP53 Walker et al., 1991; Poller et al., 1993) al., 1991; O'Malley et al., 1994) . In addition allelic imbalance (AI), thought to represent inactivation of tumour-suppressor genes, has been demonstrated at a number of loci, including TP53, not only in comedo DCIS but also in cribriform and micropapillary variants of lower nuclear grade (Radford et al., 1993; Munn et al., 1995 Munn et al., , 1996 Radford et al., 1995; Stratton et al., 1995; Zhuang et al., 1995) .
Here Holland et al. (1994) . All tumour samples were formalin fixed and paraffin embedded, and for the majority of cases a block containing normal breast tissue was also available.
described (Munn et al., 1995 Single-strand conformation polymorphism analysis Tumour DNA was screened for mutations in exons 4-9 of the TP53 gene using single-strand conformation polymorphism (SSCP) (Orita et al., 1989) . For exon 4 and 9 the following primers were used:
For exons 5 -8 two sets of primers were used, as it is thought that the position of a mutation within a fragment may influence its detection (Sheffield et al., 1993) . The sequences of these primers have previously been described . The majority of the primers used amplified products of between 100 and 250 base pairs, as this size is thought to be optimal for the detection of mutations by SSCP. For larger sequences products were digested by restriction endonucleases before gel electrophoresis. Products were radiolabelled by reducing the concentration of cold dCTP in the reaction to 10,M and adding 1 1Ci [oc-32P] dCTP. Before electrophoresis, 2 tl product were diluted with 6 MI 10 mM EDTA/0.1% sodium dodecyl sulphate (SDS) and 6 pl loading dye (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol). Samples were heat denatured for 2 min and immediately loaded on a non-denaturing polyacrylamide gel run in 0.5 x Tris-borate buffer. Products were analysed normally on several types of gel: 0.5 x MDE HydroLink (AT Biochemicals) or 8% polyacrylamide, containing 5 or 10% glycerol. Gels were either run at 15W for 8-1O h at room temperature with the use of a cooling fan, or at 4°C. After electrophoresis, gels were transferred to 3MM paper, dried at 80°C under vacuum and exposed to radiographic film.
DNA sequencing
Normal and tumour DNA were amplified for 35 cycles using the outer most set of primers. A secondary reaction in a volume of 30 ,ul, containing 0.5 jul of first round product and 5 pmol of each primer, was then amplified for twenty cycles. Products were analysed on 2% agarose gels and the fragment subsequently purified using Magic DNA Clean-up Columns (Promega). Double-stranded PCR products were sequenced using a variation of the dideoxy chain termination method (Winship, 1989) . Products were analysed on 6% denaturing polyacrylamide gels.
Immunohistochemistry
Paraffin-embedded tissue sections of 5 gM thickness were stained using both DO-I (a gift from D Lane), a murine monoclonal antibody which recognises a denaturationresistant epitope at amino acids 20-25 of human p53, and CM-I (Novocastra Labs), a rabbit polyclonal serum raised against recombinant human p53 protein (Midgley et al., 1992; Vojtesek et al., 1992) . Sections were incubated with primary antibody (undiluted and 1:800 dilutions respectively) overnight at 4°C. For both antibodies the avidin -biotinperoxidase complex was developed using 3,3-diaminobenzidine as the chromogen. Only nuclear staining was assessed. Tumours were subdivided into those with > 50% cells reactive; 20-50% positive cells; patchy staining in some ducts <20%; scant positive cells and negative. Only samples from series 1 were analysed by immunohistochemistry.
Detection of allelic imbalance Four microsatellite DNA length polymorphisms on chromosome 17p were used to detect Al: D17S926 (Gyapay et al., 1994) , TP53(AAAAT)n (Futreal et al., 1992) , TP53(CA)n (Jones and Nakamura, 1992) and D17S513 (Oliphant et al., 1991) . The primer sequences used to amplify the pentanucleotide and dinucleotide repeats within TP53 differed from those used in the original publications.
In addition, four polymorphisms were used to control for Al on the long arm of chromosome 17, as previously described (Munn et al., 1996) The examples shown were run at room temperature on a 5% polyacrylamide gel containing 10% glycerol, and on a 0.5 x MDE polyacrylamide gel containing 5% glycerol (exons 5 and 7 respectively). In this autoradiographic exposure no signal can be seen from sample 1886Cr. (b), Mutations detected by SSCP analysis were confirmed by sequencing of double-stranded PCR products; sequence changes are indicated. In case 2281 the mutation is shown on the complementary strand. In case 458 no mutation was detected in the DCIS component; however, the mutation in the invasive sample appears to be homo-or hemizygous. In contrast, the presence of the wild-type sequence, of roughly equal intensity, in case 2281 suggests that the mutation is heterozygous. N, normal; C, comedo DCIS; Cr, cribriform DCIS; I, invasive tumour. p53 expression Fifteen cases of pure DCIS from series 1 were stained with the antibodies DO-1 and CM-1 (see Table III ). In all areas of normal tissue negative staining patterns were observed. Of those eight cases (53%), which showed positive staining, the patterns of staining could be divided into four classes. The majority of those that were positive showed moderate to strong nuclear staining, which was present in at least 50% of the tumour cells (Figure 2 case also showed some cytoplasmic staining with CM-1; however, cross-reactivity of this antibody has been reported previously (Cornelis et al., 1994) . Of the cases stained, four contained a TP53 mutation. One case (6), which contained a missense mutation, had no evidence of staining. Case 2281, which had a missense mutation, and case 3805, which had a frameshift resulting in deletion of the last 50 amino acids, both showed strong nuclear staining (Figure 2b ). However, case 106, which had silent mutation, also showed positive staining, although the pattern was patchy (Figure 2a ). In addition, for five cases in which no mutation was identified by SSCP, one of which was also sequenced, positive staining was observed. (0) Figure 4a ). Both DCIS components. Case 4617 showed loss of 17q markers (Munn et al., 1996) and the cribriform component of 4681 showed loss of chromosome 1 markers (Munn et al., 1995 Eeles et al., 1994) . Molecular analysis has, in contrast, revealed a frequency of only 13-30% (Prosser et al., 1990; Varley et al., 1991; Cornelis et al., 1994) . In DCIS the reported frequency of p53 overexpression is much lower at around 10-25% (Bartek et al., 1990; Poller et al., 1993 ), although Bobrow et al. (1995 reported 50%, and there are only two reported cases in which TP53 mutations were identified in DCIS by sequencing (Davidoff et al., 1991; O'Malley et al., 1994) . Using a combination of SSCP and DNA sequence analysis of small foci of tumour cells from DCIS, we have identified TP53 mutations in four cases (11%). Those three cases in which the mutation was missense or led to a truncated protein, were all comedo DCIS of poor differentiation. The fourth case, a well-differentiated cribriform lesion, contained a silent mutation. This case has previously been reported to show AI on chromosome 1 (Munn et al., 1995) . Therefore, selection for a mutation in the gene, which is the target of Al on chromosome 1, may account for the maintenance of this TP53 mutation in the tumour. In 53% of those cases which were stained with antip53 antibodies, positive staining was observed. This frequency is significantly higher than seen in previous studies, possibly because of our small sample size. However, the majority of these cases did not appear to have TP53 mutations. A likely explanation for this may be the failure of SSCP to identify all mutations, although in previous studies of known TP53 mutants, its sensitivity is estimated to be around 90% (Moyret et al., 1994) . Also, the possibility of mutations in the regulatory region of the gene or in the remainder of the coding region cannot be eliminated. In addition, some of these cases showed staining in a small proportion of the cells in the tumour, or showed a heterogeneous pattern of staining. In such cases the presence of a mutation in a wild-type background may be difficult to detect using PCR-based techniques. Furthermore, it has been reported that overexpression of TP53 protein does occur in the absence of mutation (Barnes et al., 1992b) . This may be a result of the overexpression of a protein which binds p53 and stabilises it, e.g. MDM2, or it may be caused by the presence of DNA damage in the tumour cell. Whatever the mechanism of the observed overexpression, these results are interesting in that there are no previous reports of positive staining in cribriform DCIS, and there is only one reported case of micropapillary DCIS that shows overexpression of TP53 (Thor et al., 1992) .
In contrast, the observed frequency of AI on chromosome 17p in DCIS is similar to that reported for invasive tumours Andersen et al., 1992; Cornelis et al., 1994) . In a number of cases the TP53 gene appears to be the target of Al. However, few of these cases were found to contain a TP53 mutation. Theile et al., 1995) . Therefore, it is unclear in these cases which gene was the target of Al; however, one case did show Al at 17pl3.3 independent from TP53, suggesting that this gene may have a role in the early stages of breast tumorigenesis. A number of these cases also showed Al at all informative markers studied on 17q, and in the majority the patterns consisted of clear allele loss rather than allele imbalance, suggesting possibly that a copy of the whole chromosome had been lost. Obviously, using PCR-based techniques it cannot easily be determined whether this has been followed by duplication of the remaining homologue, but previous studies, using interphase cytogenetics, have reported polysomy for chromosome 17 in DCIS (Murphy et al., 1995) . From these data, and much of that which has previously been documented, it is evident that a large number of the genetic alterations known to occur in invasive breast tumours are already present in DCIS. This is clearly not only the case for high-grade comedo lesions. Here we have demonstrated AI on chromosome 17p in a number of well-differentiated cribriform and micropapillary lesions, both with and without associated invasive disease. Unfortunately, we failed to identify common TP53 mutations in DCIS and invasive tumourJrom the same patient, which would have provided strong evidence for the preinvasive nature of DCIS. The patterns of Al in a number of cases do, however, support this. We have also identified one case of fibroadenosis, which shows AI and displays the same pattern of allele loss in DCIS and invasive components from the same patient (6457). The relationship between benign, in situ and invasive disease is not always likely to be as simple as in 6457. Although DCIS has previously been reported to be clonal in origin (Noguchi et al., 1994) , there is clearly heterogeneity within the DCIS component, and we and others have previously reported cases in which there was loss in the benign or in situ component and not in the invasive tumour (Munn et al., 1995 (Munn et al., , 1996 Stratton et al., 1995) . It is likely, therefore, that DCIS exists as divergent populations, only some of which may acquire the changes necessary for them to become invasive carcinoma. The application of this kind of approach to lesions, such as atypical ductal hyperplasia, which are thought to be borderline between hyperplasia and neoplasia, will hopefully provide a clearer picture of the pathway of tumour development.
